Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP…
P/0250/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for deucravacitinib (Sotyktu), (EMEA-002350-PIP05-23)
Reference Number: EMA/302856/2023
![](https://www.einpresswire.com/tracking/article.gif?t=4&a=tQe8l0_J_Yem3PgF&i=c9wzmIYopgUpbeiC)